Advancing TIL Clinical Development by Generating Early Efficacy Signals in Cold Solid Tumors

• Demonstrating initial clinical feasibility of TIL therapy in colorectal and prostate cancer
• Exploring patient selection and tumor sourcing challenges in low immunogenic indications
• Translating early treatment experience into future trial design decisions

Speakers:

Lucas Arruda

Chief Scientific Officer

CuraCell Holding